IDEAYA Biosciences Inc
NASDAQ:IDYA
Intrinsic Value
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. [ Read More ]
The intrinsic value of one IDYA stock under the Base Case scenario is 9.42 USD. Compared to the current market price of 37.62 USD, IDEAYA Biosciences Inc is Overvalued by 75%.
Valuation Backtest
IDEAYA Biosciences Inc
Run backtest to discover the historical profit from buying and selling IDYA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
IDEAYA Biosciences Inc
Current Assets | 532.6m |
Cash & Short-Term Investments | 525.1m |
Receivables | 18k |
Other Current Assets | 7.5m |
Non-Current Assets | 116.7m |
Long-Term Investments | 107.5m |
PP&E | 8.4m |
Other Non-Current Assets | 782k |
Current Liabilities | 27.1m |
Accounts Payable | 6.6m |
Accrued Liabilities | 20.5m |
Non-Current Liabilities | 1.1m |
Other Non-Current Liabilities | 1.1m |
Earnings Waterfall
IDEAYA Biosciences Inc
Revenue
|
23.4m
USD
|
Operating Expenses
|
-157.8m
USD
|
Operating Income
|
-134.4m
USD
|
Other Expenses
|
21.5m
USD
|
Net Income
|
-113m
USD
|
Free Cash Flow Analysis
IDEAYA Biosciences Inc
What is Free Cash Flow?
IDYA Profitability Score
Profitability Due Diligence
IDEAYA Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
IDEAYA Biosciences Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
IDYA Solvency Score
Solvency Due Diligence
IDEAYA Biosciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
IDEAYA Biosciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDYA Price Targets Summary
IDEAYA Biosciences Inc
According to Wall Street analysts, the average 1-year price target for IDYA is 53.96 USD with a low forecast of 50.5 USD and a high forecast of 63 USD.
Ownership
IDYA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IDYA Price
IDEAYA Biosciences Inc
Average Annual Return | 19.92% |
Standard Deviation of Annual Returns | 51.22% |
Max Drawdown | -75% |
Market Capitalization | 2.8B USD |
Shares Outstanding | 74 560 304 |
Percentage of Shares Shorted | 12.74% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-05-23. The firm is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.
Contact
IPO
Employees
Officers
The intrinsic value of one IDYA stock under the Base Case scenario is 9.42 USD.
Compared to the current market price of 37.62 USD, IDEAYA Biosciences Inc is Overvalued by 75%.